Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peposertib and Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer
NCT04092270Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2020
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of peposertib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by National Cancer Institute. Primary endpoint: Incidence of adverse events at 3 years. Started May 2020; status: active, not recruiting.
02
Drugs
peposertib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT04092270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04092270.